Developing a Public Health Response to Mycoplasma genitalium

@article{Golden2017DevelopingAP,
  title={Developing a Public Health Response to Mycoplasma genitalium},
  author={Matthew R Golden and Kimberly Workowski and Gail A. Bolan},
  journal={The Journal of Infectious Diseases},
  year={2017},
  volume={216},
  pages={S420–S426}
}
Although Mycoplasma genitalium is increasingly recognized as a sexually transmitted pathogen, at present there is no defined public health response to this relatively newly identified sexually transmitted infection. Currently available data are insufficient to justify routinely screening any defined population for M. genitalium infection. More effective therapies, data on acceptability of screening and its impact on clinical outcomes, and better information on the natural history of infection… 
Mycoplasma genitalium infection
TLDR
This practice pointer provides an overview of M genitalium infection including practical advice for non-specialists on diagnosis and management and the relative ease by which this sexually transmitted infection develops resistance.
Mycoplasma genitalium Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test
TLDR
The cobas assay was highly sensitive and specific in all relevant clinical samples for the detection of M. genitalium, and was compared to a reference standard of three laboratory-developed tests.
Evaluation of molecular testing for Mycoplasma genitalium for symptomatic women
TLDR
This initial pilot study prompts the following recommendations which require further study and consideration: promotion of M. genitalium status to notifiable disease, widespread screening of female population not warranted, and antibiotic resistance testing of all positive cases.
Mycoplasma genitalium From Basic Science to Public Health: Summary of the Results From a National Institute of Allergy and Infectious Disesases Technical Consultation and Consensus Recommendations for Future Research Priorities.
TLDR
The most important recommendation resulting from this Technical Consultation is the initiation of clinical trials designed to determine definitively whether screening for and treatment of M. genitalium infections in women and their sexual partners improve reproductive health inWomen and/or prevent human immunodeficiency virus transmission.
Infections caused by Chlamydia trachomatis (including lymphogranuloma venereum) and Mycoplasma genitalium
TLDR
The routine clinical diagnosis of urethritis and cervicitis must be combined with the active search for the causal agent in men with symptoms of dysuria or proctitis, and in women with pelvic inflammatory disease, and sexually transmitted infection screening must be widely implemented in those population groups with a high prevalence of sexually transmitted infections.
Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review
TLDR
Overall, macrolide resistance is rapidly increasing in this region, where many countries are exceeding 50% and limited data regarding fluoroquinolone resistance estimate a prevalence of 5% (interquartile range, 5–6%).
Infections caused by Chlamydia trachomatis (including lymphogranuloma venereum) and Mycoplasma genitalium.
TLDR
The routine clinical diagnosis of urethritis and cervicitis must be combined with the active search for the causal agent in men with symptoms of dysuria or proctitis, and in women with pelvic inflammatory disease, and sexually transmitted infection screening must be widely implemented in those population groups with a high prevalence of sexually transmitted infections.
Diagnosis of some genital-tract infections: part 2. Molecular tests and the new challenges
TLDR
It is argued that a shift from specialist-led to patient- and non-specialist-led STI management, in the presence of a clinical leadership vacuum, has increased the risk of inappropriate and unnecessary treatment which will drive macrolide, tetracycline and metronidazole antimicrobial resistance.
Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study
TLDR
There is insufficient data to justify MG testing among asymptomatic individuals and current STI guidelines should be followed until evidence shows the cost and effectiveness of screening, but higher risk subpopulations which might be targets for MG screening are identified.
Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis
TLDR
The low estimated prevalence of M. genitalium in the general population, pregnant women and asymptomatic attenders at clinics does not support expansion of testing to these groups, and can inform testing guidelines for M. genitalsium testing.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Management of Mycoplasma genitalium infections – can we hit a moving target?
TLDR
There is a critical need for trials of combinations of existing registered drugs and new antimicrobial compounds, implementation of diagnostic testing combined with molecular detection of resistance, and antimicrobial surveillance.
Mycoplasma genitalium: An Emerging Cause of Sexually Transmitted Disease in Women
TLDR
Collectively, M. genitalium is highly prevalent in high- and low-risk populations, and should be considered an etiologic agent of select reproductive tract disease syndromes in women.
Mycoplasma genitalium
  • C. Gaydos
  • Medicine
    The Journal of infectious diseases
  • 2017
TLDR
This review covers available molecular methods for the diagnosis of M. genitalium and assays to predict the antibiotic susceptibility to azithromycin and recommends that more commercial Assays to both diagnose this organism and guide treatment choices should be developed and made available through regulatory approval.
Mycoplasma genitalium: should we treat and how?
TLDR
Existing data on infection in women are limited and inconsistent but suggest that M. genitalium is associated with urethritis, cervicitis, pelvic inflammatory disease, and possibly female infertility, and available data suggest that azithromycin is superior to doxycycline in treating M. genitalsium infection.
European guideline on Mycoplasma genitalium infections
Mycoplasma genitalium infection contributes to 10–35% of non-chlamydial non-gonococcal urethritis in men. In women, M. genitalium is associated with cervicitis and pelvic inflammatory disease (PID).
2016 European guideline on Mycoplasma genitalium infections
Mycoplasma genitalium infection contributes to 10–35% of non‐chlamydial non‐gonococcal urethritis in men. In women, M. genitalium is associated with cervicitis and pelvic inflammatory disease (PID).
Fluoroquinolone and Macrolide Resistance-Associated Mutations in Mycoplasma genitalium
TLDR
The results indicate that further surveillance is needed, and testing and treatment protocols for M. genitalium infections may need to be reviewed, as well as support anecdotal clinical reports of azithromycin and moxifloxacin treatment failures in Sydney.
Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection.
TLDR
M genitalium was more prevalent than Neisseria gonorrhoeae but less prevalent than Chlamydia trachomatis, and it was strongly associated with sexual activity.
Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian women.
TLDR
Although MG incidence was relatively low, testing should be recommended for women considered to be at increased risk based on sexual history and the results suggest that organism load might be important in azithromycin treatment failure.
Transmission and Selection of Macrolide Resistant Mycoplasma genitalium Infections Detected by Rapid High Resolution Melt Analysis
TLDR
A rapid high resolution melt analysis assay targeting resistance mutations in the MG 23S rRNA gene was developed and validated by examining pre- and post-treatment archived samples from MG-infected patients, and was able to detect all mutational changes determined in this study by DNA sequencing.
...
1
2
3
4
5
...